Mangoceuticals Statistics
Total Valuation
Mangoceuticals has a market cap or net worth of $5.20 million. The enterprise value is $4.02 million.
Important Dates
The next estimated earnings date is Thursday, May 14, 2026, after market close.
| Earnings Date | May 14, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Mangoceuticals has 15.39 million shares outstanding. The number of shares has increased by 334.64% in one year.
| Current Share Class | 15.39M |
| Shares Outstanding | 15.39M |
| Shares Change (YoY) | +334.64% |
| Shares Change (QoQ) | +15.43% |
| Owned by Insiders (%) | 18.01% |
| Owned by Institutions (%) | 6.50% |
| Float | 10.11M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 11.41 |
| Forward PS | n/a |
| PB Ratio | 0.35 |
| P/TBV Ratio | 5.37 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 8.82 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.74, with a Debt / Equity ratio of 0.02.
| Current Ratio | 1.74 |
| Quick Ratio | 1.67 |
| Debt / Equity | 0.02 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -169.97 |
Financial Efficiency
Return on equity (ROE) is -141.66% and return on invested capital (ROIC) is -74.13%.
| Return on Equity (ROE) | -141.66% |
| Return on Assets (ROA) | -69.91% |
| Return on Invested Capital (ROIC) | -74.13% |
| Return on Capital Employed (ROCE) | -115.76% |
| Weighted Average Cost of Capital (WACC) | 18.72% |
| Revenue Per Employee | $152,007 |
| Profits Per Employee | -$7.27M |
| Employee Count | 3 |
| Asset Turnover | 0.03 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -84.28% in the last 52 weeks. The beta is 2.55, so Mangoceuticals's price volatility has been higher than the market average.
| Beta (5Y) | 2.55 |
| 52-Week Price Change | -84.28% |
| 50-Day Moving Average | 0.40 |
| 200-Day Moving Average | 1.35 |
| Relative Strength Index (RSI) | 45.62 |
| Average Volume (20 Days) | 19,017,407 |
Short Selling Information
The latest short interest is 1.22 million, so 7.94% of the outstanding shares have been sold short.
| Short Interest | 1.22M |
| Short Previous Month | 1.74M |
| Short % of Shares Out | 7.94% |
| Short % of Float | 12.09% |
| Short Ratio (days to cover) | 0.06 |
Income Statement
In the last 12 months, Mangoceuticals had revenue of $456,021 and -$21.82 million in losses. Loss per share was -$2.17.
| Revenue | 456,021 |
| Gross Profit | 250,386 |
| Operating Income | -17.59M |
| Pretax Income | -20.64M |
| Net Income | -21.82M |
| EBITDA | -15.87M |
| EBIT | -17.59M |
| Loss Per Share | -$2.17 |
Full Income StatementBalance Sheet
The company has $1.49 million in cash and $307,823 in debt, with a net cash position of $1.18 million or $0.08 per share.
| Cash & Cash Equivalents | 1.49M |
| Total Debt | 307,823 |
| Net Cash | 1.18M |
| Net Cash Per Share | $0.08 |
| Equity (Book Value) | 15.20M |
| Book Value Per Share | 0.96 |
| Working Capital | 656,866 |
Full Balance SheetCash Flow
| Operating Cash Flow | -5.85M |
| Capital Expenditures | n/a |
| Depreciation & Amortization | 2.00M |
| Net Borrowing | 562,500 |
| Free Cash Flow | -5.90M |
| FCF Per Share | -$0.38 |
Full Cash Flow StatementMargins
| Gross Margin | 54.91% |
| Operating Margin | -3,858.11% |
| Pretax Margin | -4,526.86% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
